This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Cardiovascular System  • Statistics and Research Methods  • Prognosis/ Outcomes  • Drug Therapy, Other  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

Bertram Pitt, MD

Arch Intern Med. 2008;168(22):2431-2432.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Treatment with BBs has been shown to reduce cardiovascular mortality and hospitalizations for HF in large-scale, placebo-controlled, randomized trials of patients with HF caused by left ventricular systolic dysfunction (LVSD).^1-3 β-Blockers, along with angiotensin-converting enzyme (ACE) inhibitors⁴ and aldosterone-blocking agents,⁵ reduce mortality and hospitalization for HF in patients with HF caused by LVSD and have been given a class 1 indication in the American College of Cardiology/American Heart Association guidelines.⁶ However, despite the overwhelming evidence supporting the use of BBs in patients with HF caused by LVSD, many patients who seem to qualify for their use do not receive them.⁷ In part, this is the result of perceived tolerability, cost, a revulsion on the part of many patients and physicians to the use of polypharmacy, and the belief that randomized clinical trials in circumscribed patient populations do not reflect real-world conditions and do not apply to patients . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Conflicts of Interest Need to Be Reported Reliably
Jeff Whittle
Arch Intern Med. 2009;169(11):1078-1079.
EXTRACT | FULL TEXT  

Conflicts of Interest Need to Be Reported Reliably—Reply
Bertram Pitt
Arch Intern Med. 2009;169(11):1079.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Comparative Effectiveness of β-Blockers in Elderly Patients With Heart Failure
Judith M. Kramer, Lesley H. Curtis, Carla S. Dupree, David Pelter, Adrian Hernandez, Mark Massing, and Kevin J. Anstrom
Arch Intern Med. 2008;168(22):2422-2428.
ABSTRACT | FULL TEXT  

Comparative Effectiveness of β-Blockers in Elderly Patients With Heart Failure—Invited Commentary
Brian L. Strom
Arch Intern Med. 2008;168(22):2428-2431.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Conflicts of Interest Need to Be Reported Reliably--Reply
Pitt
Arch Intern Med 2009;169:1079-1079.
FULL TEXT  

Conflicts of Interest Need to Be Reported Reliably
Whittle
Arch Intern Med 2009;169:1078-1079.
FULL TEXT